Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. The company is currently studying three biologic product candidates in the clinic for the treatment of osteoporosis, osteogenesis imperfecta (OI), and spinal fusion.
Leveraging the team's extensive experience and scientific acumen in novel drug development, Angitia is committed to providing groundbreaking therapies to satisfy key unmet medical needs. The company's mission is to discover, develop, and commercialize breakthrough therapeutics for patients with serious musculoskeletal conditions.
Angitia's vision is "Innovation for patients," guided by core values of integrity, collaboration, and innovation. The company operates globally with research and development efforts spanning multiple continents.